Intrapleural administration of lipoplatin in an animal model

Froudarakis, Marios; Greillier, L.; Monjanel-Mouterde, Suzanne; Koutsopoulos, Anastasios; Devictor-Pierre, Bénédicte; Guilhaumou, Romain; Karpathiou, Georgia; Botaitis, Sotirios; Astoul, Philippe

doi:10.1016/j.lungcan.2010.07.010

Cited by 8 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wistar rats were treated with doses of 10 mg/kg lipoplatin (intravenously) versus 10 or 20 mg/kg lipoplatin (intrapleurally) corresponding to 60 and 120 mg/m 2 , respectively, in humans. The authors noted minor fibrotic changes in the pleura of rats injected intrapleurally, and mild kidney changes in rats injected intravenously, as expected [38]. …”

Section: Preclinical Studiessupporting

confidence: 67%

Lipoplatin Formulation Review Article

Stathopoulos

Boulikas

2012

Journal of Drug Delivery

178

125

View full text Add to dashboard Cite

Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications. For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.

show abstract

Section: Preclinical Studiessupporting

confidence: 67%

Lipoplatin Formulation Review Article

Stathopoulos

Boulikas

2012

Journal of Drug Delivery

178

125

View full text Add to dashboard Cite

show abstract

“…Few studies have directly compared intrapleural and intravenous delivery of drugs; but these studies have consistently shown that intrapleural administration reduces peak plasma levels, reduces systemic toxicity and yields a higher drug concentration at the pleura compared with intravenous administration. [12][13][14]50,53 The position of the tumour cells adjacent to the pleural cavity provides a unique opportunity to administer therapeutics directly to the tumour site. Therapeutic delivery via an existing pleura catheter or at pleurodesis means patients could be given tumour-site targeted therapies while also avoiding any additional needling of the pleura.…”

Section: Discussionmentioning

confidence: 99%

“…Intrapleural drug delivery is an attractive alternative to intravenous therapies for pleural cancers because i) drugs reach higher concentrations at the site of the tumor ii) concentrations are sustained for longer periods due to a slower clearance rate and iii) there are reduced systemic toxicities. [12][13][14][15] Numerous drugs including paclitaxel, bevacizumab and cisplatin have been administered into the pleural space in clinical trial settings to control malignant pleural effusion, alleviate symptoms, or slow disease progression. 12,[15][16][17][18][19][20][21][22][23][24][25] To the best of our knowledge, the direct administration of curcumin into the pleural cavity has never been reported.…”

Section: Introductionmentioning

confidence: 99%

<p>The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin</p>

Hocking

Tommasi

Sordillo

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Malignant pleural effusion (MPE) is the accumulation of fluid in the pleural cavity as a result of malignancies affecting the lung, pleura and mediastinal lymph nodes. Curcumin, a compound found in turmeric, has anti-cancer properties that could not only treat MPE accumulation but also reduce cancer burden. To our knowledge, direct administration of curcumin into the pleural cavity has never been reported, neither in animals nor in humans. Purpose: To explore the compartmental distribution, targeted pharmacokinetics and the safety profile of liposomal curcumin following intrapleural and intravenous administration. Methods: Liposomal curcumin (16 mg/kg) was administered into Fischer 344 rats by either intrapleural injection or intravenous infusion. The concentration of curcumin in plasma and tissues (lung, liver and diaphragm) were measured using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS). Blood and tissues were examined for pathological changes. Results: No pleural or lung pathologies were observed following intrapleural liposomal curcumin administration. Total curcumin concentration peaked 1.5 hrs after the administration of intrapleural liposomal curcumin and red blood cell morphology appeared normal. A red blood cells abnormality (echinocytosis) was observed immediately and at 1.5 hrs after intravenous infusion of liposomal curcumin. Conclusion: These results indicate that liposomal curcumin is safe when administered directly into the pleural cavity and may represent a viable alternative to intravenous infusion in patients with pleural-based tumors.

show abstract

“…According to it, a semi-quantitative system of 0=absence, 1=mild, 2=moderate, 3=severe is applied for each parameter. A final score was attributed as the sum of all values (10).…”

Section: Histopathological Evaluationmentioning

confidence: 99%

Differences in the pathological patterns of non-specific pleuritis (NSP).

Karpathiou¹,

Hathroubi²,

Patoir³

et al. 2018

Pleural and Mediastinal Malignancies

Self Cite

View full text Add to dashboard Cite

Background: A pleural biopsy without granulomatous inflammation or tumor cells is interpreted as "non-specific pleuritis" (NSP), a diagnosis without any specificity, often frustrating for physicians. However, varying histological features are found in NSPs with unknown significance. Objectives: To describe the detailed microscopic features of NSP and correlate them with the underlying etiology. Material and methods: 100 patients diagnosed with NSP after pleural biopsy, were retrospectively evaluated. A benign cause of pleural effusion was attributed. Histological features evaluated were inflammation, fibrosis, vascular proliferation, haemorrhage, fibrin, oedema and mesothelial hyperplasia. A semi-quantitative scoring was applied. Results: Bacterial-caused and autoimmune disease-associated NSPs showed the higher score followed by viral and drug-induced conditions, while pneumothorax and cardiac-induced NSP showed the lower score (p<0.0001). The degree of fibrosis was higher in bacterial NSP, and the type of fibrosis was cellular in this group (p=0.006). Vascular proliferation differed between groups (p<0.0001), with bacterial NSP showing the higher one. Conclusion: Histological findings differ significantly between the varying etiologies of NSP, and this may be used to suggest identify the cause of the effusion.

show abstract

Intrapleural administration of lipoplatin in an animal model

Cited by 8 publications

References 30 publications

Lipoplatin Formulation Review Article

Lipoplatin Formulation Review Article

<p>The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin</p>

Differences in the pathological patterns of non-specific pleuritis (NSP).

Contact Info

Product

Resources

About